BeiGene
BGNE
#881
Rank
โ‚น1.860 T
Marketcap
โ‚น16,946
Share price
1.71%
Change (1 day)
5.70%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of June 2024 : โ‚น282.40 B

According to BeiGene 's latest financial reports the company has โ‚น282.40 B in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$โ‚น294.47 B-18.81%
2022-12-31$โ‚น362.72 B-20.63%
2021-12-31$โ‚น457.01 B61.78%
2020-12-31$โ‚น282.49 B305.66%
2019-12-31$โ‚น69.63 B-42.91%
2018-12-31$โ‚น121.98 B179.21%
2017-12-31$โ‚น43.68 B82.17%
2016-12-31$โ‚น23.98 B385.64%
2015-12-31$โ‚น4.93 B202.82%
2014-12-31$โ‚น1.63 B-168.14%
2013-12-31$-โ‚น2.4 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
โ‚น0.50 B-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น117.05 B-58.55%๐Ÿ‡บ๐Ÿ‡ธ USA